Dr. Bockorny is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
330 Brookline Avenue
Boston, MA 02215Phone+1 617-667-7000
Summary
- Dr. Bruno Bockorny is an oncologist in Boston, MA and is affiliated with Beth Israel Deaconess Medical Center. He received his medical degree from Federal University of Rio de Janeiro School of Medical Sience and has been in practice 13 years. He specializes in gastrointestinal cancer and sarcoma. He has more than 30 publications and over 500 citings.
Education & Training
Fed Univ Rio de Janeiro- Sch Med SciClass of 2007
Certifications & Licensure
MA State Medical License 2017 - 2026
ME State Medical License 2020 - 2021
Clinical Trials
- AGEN1423 Plus Balstilimab With or Without Chemo in Pancreatic Cancer Start of enrollment: 2024 Apr 01
Roles: Principal Investigator, Sponsor-Investigator, Contact
Publications & Presentations
PubMed
- A large-scale proteomics resource of circulating extracellular vesicles for biomarker discovery in pancreatic cancer.Bruno Bockorny, Lakshmi Muthuswamy, Ling Huang, Marco Hadisurya, Christine Maria Lim
Elife. 2024-12-18 - First results of migoprotafib, a potent and highly selective Src homology-2 domain-containing phosphatase 2 (SHP2) inhibitor in patients with advanced solid tumors.Melissa L Johnson, Beni B Wolf, Judy S Wang, Alexander Philipovskiy, Geoffrey I Shapiro
Molecular Cancer Therapeutics. 2024-12-05 - A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: the AVATAR Trial.Francesca Sarno, Jair Tenorio, Sofia Perea, Laura Medina, Roberto Pazo-Cid
Clinical Cancer Research. 2024-11-14
Press Mentions
Agenus (AGEN) Q1 2023 Earnings Call TranscriptMay 9th, 2023- Novel Strategies Show Winning Potential in Ovarian CancerMarch 28th, 2023
- Agenus’ Botensilimab in Combination with Balstilimab Shows 33% Durable Responses in Ovarian CancerMarch 27th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
